CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for YanAn Bicon Pharmaceutical Listed Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

YanAn Bicon Pharmaceutical Listed Co
North Building of Financial Bureau
No.18, Zhongwu South Road, Xinyi City
Phone: +86 75586951472p:+86 75586951472 XI'AN, SXI  710065  China Ticker: 002411002411
This company is no longer actively traded on any major stock exchange.
Business Summary
YanAn Bicon Pharmaceutical Listed Company, formerly JiangSu Bicon Pharmaceutical Listed Company, is a China-based company principally engaged in the research and development, manufacture and distribution of medical products, new energy materials and drug intermediates. The Company operates its businesses through three segments. The Pharmaceuticals segment provides circulatory system, digestive system, respiratory system, nervous system and ophthalmic products. The New Materials segment mainly consists of lithium hexafluorophosphate, high-strength and high modulus polyethylene fibers and others. The Pharmaceutical Intermediates segment consists of 7-ADCA, benzaldehyde, 5.5-dimethylhydantion and trichloropyridine. The Company distributes its products mainly in domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
5912 Drug stores and proprietary stores
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2819 Industrial inorganic chemicals, not elsewhere classified
2869 Industrial organic chemicals, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Acting Secretary of the Board WenxiongHan 61 4/14/2023 7/22/2021
Finance Director XiFang 51 10/22/2021 10/22/2021
Vice President, Director XinxueQuan 47 7/22/2021 7/5/2021
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2,901 (As of 12/31/2022)
Outstanding Shares: 1,532,283,909 (As of 3/31/2023)
Shareholders: 66,370
Stock Exchange: SHE
Fax Number: +86 75586951514


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024